Transcode Therapeutics

Yahoo Finance • 5 months ago

TransCode's TTX-MC138 To Enter Phase 2a Trial As Part Of Quantum Leap PRE-I-SPY Platform

(RTTNews) - TransCode Therapeutics, Inc. (RNAZ) and Quantum Leap Healthcare Collaborative, on Friday, announced a collaboration to evaluate TTX-MC138 in a Phase 2a dose-expansion trial. TTX-MC138, TransCode's lead therapeutic candidate, w... Full story

Yahoo Finance • 7 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index and the Health Car PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 7 months ago

Sector Update: Health Care Stocks Advance Wednesday Afternoon

Health care stocks rose Wednesday afternoon, with the NYSE Health Care Index adding 0.3% and the Hea PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 years ago

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

BOSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the third quarter... Full story

Yahoo Finance • 3 years ago

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced The Nasdaq Hearings Pan... Full story

Yahoo Finance • 3 years ago

TransCode Therapeutics Announces Public Offering of Common Stock

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the commencement of an... Full story

Yahoo Finance • 3 years ago

TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced significantly improved survival in muri... Full story

Yahoo Finance • 3 years ago

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

BOSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced preliminary results with its lead thera... Full story

Yahoo Finance • 3 years ago

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

BOSTON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported successful treatment of preclinical melan... Full story

Yahoo Finance • 3 years ago

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

BOSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its prev... Full story

Yahoo Finance • 3 years ago

TransCode Therapeutics Announces Pricing of $8 Million Public Offering

BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of its und... Full story

Yahoo Finance • 3 years ago

TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138

BOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today positive results with its lead therape... Full story

Yahoo Finance • 3 years ago

TransCode Therapeutics Announces First Subject Dosed with Radiolabeled TTX-MC138 in First-In-Human Clinical Trial

BOSTON, Aug. 23, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the dosing of the first subject in its... Full story

Yahoo Finance • 3 years ago

TransCode Therapeutics Reports Second Quarter 2023 Results; Provides Business Update

BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today reported financial results for the second quarter... Full story

Yahoo Finance • 3 years ago

TransCode Therapeutics Announces Publication of New Data Supporting the Use of TTX-MC138 for the Treatment of Metastatic Breast Cancer

BOSTON, June 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, announced today publication of new data relevant to its... Full story

Yahoo Finance • 3 years ago

TransCode Therapeutics Announces Closing of $7 Million Public Offering

BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previ... Full story

Yahoo Finance • 3 years ago

TransCode Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial

BOSTON, April 27, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary delivery system platform to defeat cancer, announced today that it has r... Full story

Yahoo Finance • 3 years ago

TransCode Therapeutics Announces Strategic Expansion of its Product Portfolio

BOSTON, April 26, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a leading clinical-stage oncology company committed to using its proprietary platform delivery system to defeat cancer, today announced a strategic e... Full story

Yahoo Finance • 3 years ago

TransCode Therapeutics to present at AACR Annual Meeting 2023

BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it will present new results and... Full story

Yahoo Finance • 3 years ago

TransCode Therapeutics Receives Notice of Award from National Institutes of Health (NIH) for Third Year of Grant to Support Clinical Evaluation of TTX-MC138

BOSTON, April 05, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has been awarded the third ye... Full story